Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 19 min ago
Peer-reviewedCC BYMaterials today. Bio

Chirality and morphology-dependent siRNA delivery for targeted lung cancer therapy with intrinsically chiral gold nanoparticles.

  • Qiusha Li1
  • Jinglei Xu1
  • En Zhang2
  • Chen Liu1
  • Wuyi Liu1
  • Kaichuan Yan1
  • Doudou Xu3
  • Jian Wang1
  1. 1Key Laboratory of Biomedical Analytics (Southwest University), Chongqing Science and Technology Bureau, College of Pharmaceutical Sciences, Southwest University, Chongqing, 400715, PR China.
  2. 2Chongqing Key Laboratory of Quality Control and Safety Evaluation of Active Pharmaceutical Ingredients, Chongqing Institute for Food and Drug Control, Chongqing, 401121, PR China.
  3. 3Chongqing Pharmaceutical Science Technology School, Chongqing, 400700, PR China.
Read full textPDFDOICite

Abstract

The clinical translation of RNA interference (RNAi) for lung cancer treatment remains hampered by the lack of delivery vectors that concurrently optimize cellular uptake, target specificity, and in vivo stability. This work reports an intrinsically chiral gold nanoparticle (Au NP) platform with precisely controlled morphology for targeted siRNA delivery. Through a full 2 × 2 factorial design (2 chiralities × 2 morphologies), the work decouples the individual and combined contributions of these two parameters. It is found that right-handed chiral nanoparticles (D-NPs) show significantly faster cellular internalization and higher gene silencing potency than left-handed (L-NPs) and achiral (DL-NPs) counterparts. Beyond chirality, nanoparticle morphology serves as an equally critical parameter: the rhombicuboctahedral (RCO) architecture yields markedly higher silencing efficacy than cubic counterparts with D-chirality. Furthermore, proteomic analysis revealed that Au RCO nanoparticles with different chirality displayed distinct functional enrichment profiles. By D-RCO combination with minimal surface modification, siRNA targeting PD-L1 achieves potent knockdown and robust inhibition of H460 lung cancer proliferation both in vitro and in vivo. This work establishes chirality and morphology as co-designable parameters for gene delivery and provides a mechanistic blueprint for translating chiral nanomaterials into solid tumor therapy.

Related

  1. Engineering morphology of tetrasulfide-incorporated mesoporous silica nanoparticles for enhanced mRNA delivery
    Z. Cao, S. Saarela, J. Wang +7
    bioRxivPreprintCC BYFull textGeneral biochemistrybioRxiv
  2. MgATP/MgADP-dependent conformational dynamics and intrinsically disordered regions of vascular KATP channels revealed by cryoEM
    C. M. Driggers, Y.-Y. Kuo, Z. Yang +4
    bioRxivPreprintCC BY-NCFull textMolecular biology & gene regulationbioRxiv
  3. Non-coding RNA delivery via lipid nanoparticles: a novel strategy for cancer immunotherapy
    Yufei Sheng, Lulu Yang, Boyang Wang +3
    Cancer Biology & MedicinePeer-reviewedCC BY-NCFull text1 citedMolecular biology & gene regulationDOAJ
  4. Targeted Gastrointestinal Delivery of mRNA Lipid Nanoparticles Enables Systemic Vaccination and Glucagon-like Peptide-1 Metabolic Therapy.
    Abdulraouf M Abbas, Ramy Ghanim, Sebastian Rudden +6
    ACS nanoPeer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMC
  5. Ultrasound-Triggered piRNA Delivery Using Biomimetic Phase-Changeable Nanoparticles for Theranostics of Myocardial Infarction.
    Yajun Zhang, Hongzhao Qi, Yanyan Yang +8
    Advanced science (Weinheim, Baden-Wurttemberg, Germany)Peer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMC

Cite

BibTeXRIS
BibTeX
@article{li2026chirality,
  title = {{Chirality and morphology-dependent siRNA delivery for targeted lung cancer therapy with intrinsically chiral gold nanoparticles.}},
  author = {Qiusha Li and Jinglei Xu and En Zhang and Chen Liu and Wuyi Liu and Kaichuan Yan and Doudou Xu and Jian Wang},
  journal = {Materials today. Bio},
  year = {2026},
  month = oct,
  doi = {10.1016/j.mtbio.2026.103745},
  url = {https://europepmc.org/article/MED/42904094},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Chirality and morphology-dependent siRNA delivery for targeted lung cancer therapy with intrinsically chiral gold nanoparticles.
AU  - Qiusha Li
AU  - Jinglei Xu
AU  - En Zhang
AU  - Chen Liu
AU  - Wuyi Liu
AU  - Kaichuan Yan
AU  - Doudou Xu
AU  - Jian Wang
PY  - 2026
DA  - 2026/10/09
JO  - Materials today. Bio
DO  - 10.1016/j.mtbio.2026.103745
UR  - https://europepmc.org/article/MED/42904094
AB  - The clinical translation of RNA interference (RNAi) for lung cancer treatment remains hampered by the lack of delivery vectors that concurrently optimize cellular uptake, target specificity, and in vivo stability. This work reports an intrinsically chiral gold nanoparticle (Au NP) platform with precisely controlled morphology for targeted siRNA delivery. Through a full 2 × 2 factorial design (2 chiralities × 2 morphologies), the work decouples the individual and combined contributions of these two parameters. It is found that right-handed chiral nanoparticles (D-NPs) show significantly faster cellular internalization and higher gene silencing potency than left-handed (L-NPs) and achiral (DL-NPs) counterparts. Beyond chirality, nanoparticle morphology serves as an equally critical parameter: the rhombicuboctahedral (RCO) architecture yields markedly higher silencing efficacy than cubic counterparts with D-chirality. Furthermore, proteomic analysis revealed that Au RCO nanoparticles with different chirality displayed distinct functional enrichment profiles. By D-RCO combination with minimal surface modification, siRNA targeting PD-L1 achieves potent knockdown and robust inhibition of H460 lung cancer proliferation both in vitro and in vivo. This work establishes chirality and morphology as co-designable parameters for gene delivery and provides a mechanistic blueprint for translating chiral nanomaterials into solid tumor therapy.
SN  - 2590-0064
ER  -